These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 25840609

  • 1. Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks.
    Murray L, Sethugavalar B, Robertshaw H, Bayman E, Thomas E, Gilson D, Prestwich RJ.
    Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):401-10. PubMed ID: 25840609
    [Abstract] [Full Text] [Related]

  • 2. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy.
    Campbell BA, Hornby C, Cunninghame J, Burns M, MacManus M, Ryan G, Lau E, Seymour JF, Wirth A.
    Ann Oncol; 2012 May; 23(5):1259-1266. PubMed ID: 21980193
    [Abstract] [Full Text] [Related]

  • 3. Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma.
    Mazonakis M, Lyraraki E, Damilakis J.
    Med Phys; 2017 Jul; 44(7):3866-3874. PubMed ID: 28493609
    [Abstract] [Full Text] [Related]

  • 4. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.
    Hoppe BS, Flampouri S, Su Z, Morris CG, Latif N, Dang NH, Lynch J, Li Z, Mendenhall NP.
    Int J Radiat Oncol Biol Phys; 2012 May 01; 83(1):260-7. PubMed ID: 22014950
    [Abstract] [Full Text] [Related]

  • 5. Involved-nodal radiation therapy leads to lower doses to critical organs-at-risk compared to involved-field radiation therapy.
    Mulvihill DJ, McMichael K, Goyal S, Drachtman R, Weiss A, Khan AJ.
    Radiother Oncol; 2014 Aug 01; 112(2):279-83. PubMed ID: 25082095
    [Abstract] [Full Text] [Related]

  • 6. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients.
    Weber DC, Johanson S, Peguret N, Cozzi L, Olsen DR.
    Int J Radiat Oncol Biol Phys; 2011 Oct 01; 81(2):490-7. PubMed ID: 20800383
    [Abstract] [Full Text] [Related]

  • 7. Probability of carcinogenesis due to involved field and involved site radiation therapy techniques for supra- and infradiaphragmatic Hodgkin's disease.
    Kourinou KM, Mazonakis M, Lyraraki E, Papadaki HΑ, Damilakis J.
    Phys Med; 2019 Jan 01; 57():100-106. PubMed ID: 30738513
    [Abstract] [Full Text] [Related]

  • 8. Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma.
    Maraldo MV, Aznar MC, Vogelius IR, Petersen PM, Specht L.
    Int J Radiat Oncol Biol Phys; 2013 Mar 15; 85(4):1057-65. PubMed ID: 23200817
    [Abstract] [Full Text] [Related]

  • 9. Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin's lymphoma with mediastinal involvement.
    Lu NN, Li YX, Wu RY, Zhang XM, Wang WH, Jin J, Song YW, Fang H, Ren H, Wang SL, Liu YP, Liu XF, Chen B, Dai JR, Yu ZH.
    Int J Radiat Oncol Biol Phys; 2012 Sep 01; 84(1):210-6. PubMed ID: 22436783
    [Abstract] [Full Text] [Related]

  • 10. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma.
    Maraldo MV, Brodin NP, Aznar MC, Vogelius IR, Munck af Rosenschöld P, Petersen PM, Specht L.
    Ann Oncol; 2013 Aug 01; 24(8):2113-8. PubMed ID: 23619032
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma.
    Paumier A, Ghalibafian M, Beaudre A, Ferreira I, Pichenot C, Messai T, Lessard NA, Lefkopoulos D, Girinsky T.
    Int J Radiat Oncol Biol Phys; 2011 May 01; 80(1):199-205. PubMed ID: 21481723
    [Abstract] [Full Text] [Related]

  • 13. Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma.
    Houlihan OA, Ntentas G, Cutter DJ, Daly P, Gillham C, McArdle O, Duane FK.
    Clin Transl Oncol; 2023 May 01; 25(5):1368-1377. PubMed ID: 36585562
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study.
    Weber DC, Peguret N, Dipasquale G, Cozzi L.
    Int J Radiat Oncol Biol Phys; 2009 Dec 01; 75(5):1578-86. PubMed ID: 19596171
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma.
    Maraldo MV, Brodin NP, Vogelius IR, Aznar MC, Munck Af Rosenschöld P, Petersen PM, Specht L.
    Int J Radiat Oncol Biol Phys; 2012 Jul 15; 83(4):1232-7. PubMed ID: 22270170
    [Abstract] [Full Text] [Related]

  • 18. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.
    Koeck J, Abo-Madyan Y, Lohr F, Stieler F, Kriz J, Mueller RP, Wenz F, Eich HT.
    Int J Radiat Oncol Biol Phys; 2012 May 01; 83(1):268-76. PubMed ID: 22079733
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk.
    Filippi AR, Ragona R, Piva C, Scafa D, Fiandra C, Fusella M, Giglioli FR, Lohr F, Ricardi U.
    Int J Radiat Oncol Biol Phys; 2015 May 01; 92(1):161-8. PubMed ID: 25863763
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.